Latest News for: bio

Edit

ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and ...

Canada Newswire 26 Dec 2025
ABL Bio and Lilly are currently conducting joint research and development on multiple therapeutic candidates leveraging the Grabody platform across various modalities ... About ABL Bio ... SOURCE ABL Bio, Inc.
Edit

‘Hobson’s choice’: Mirwaiz says authorities forced removal of Hurriyat reference from X bio

Deccan Herald 26 Dec 2025
<p>Srinagar. A day after removing the reference to “chairman, All Parties <a href= .
Edit

ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly

PR Newswire 26 Dec 2025
ABL Bio and Lilly are currently conducting joint research and development on multiple therapeutic candidates leveraging the Grabody platform across various modalities ... About ABL Bio ... SOURCE ABL Bio, Inc.
Edit

Gundry MD Bio Complete 3 Reviews: 2,400+ Positive Reviews, Users Rave About Improved Digestion, Energy ...

Morgan Citizen 24 Dec 2025
Why Dr. Steven Gundry's Probiotic, Prebiotic & Postbiotic "Triple-Action" Formula is Transforming Gut Health and Boosting Overall Wellness*✝ ... .
Edit

OCEN BIO Stem Cell Treatments Bridges the Gap Between Biology and Beauty

GetNews 24 Dec 2025
Today, OCEN BIO Stem Cell Treatments are erasing that divide ... But at OCEN BIO, we understand that the exterior is just a reflection of the foundation ... About OCEN BIO Stem Cell Treatments ... OCEN BIO.
Edit

Material Agreement (Form 8-K) (INmune Bio Inc)

Public Technologies 23 Dec 2025
). Item 1.01 Entry into a Material Definitive Agreement. On December 22, 2025, INmune Bio Inc ... As consideration for the Warrant Amendment, the holders paid the Company $0.05 per April 2024 Warrant, for aggregate proceeds of $67,416 ... INmune Bio Inc.
Edit

Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory ...

Nasdaq Globe Newswire 23 Dec 2025
FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613 ... .
×